Contract

Director – Business Operations & Strategy

Lirio

Lirio

51-200 employees

Behavioral-AI health engagement personalisation engine

Compensation Overview

$150k - $180k/yr

No H1B Sponsorship

Tennessee, USA

Hybrid

Hybrid option for Tennessee residents.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Excel/Numbers/Sheets
Financial Modeling

Get referred to Lirio

See people who can refer or advise you

Requirements
  • 5+ years of experience in Legal Operations, Commercial Finance Operations, Sales Operations, or a similar in-house role, ideally in a fast-paced technology company
  • BS/BA in Finance, Business, or Accounting
  • Deep expertise in P&L analysis, budgeting, and financial modeling
  • Ability to translate complex "legalese" into clear business cases for executive leadership; proven ability to translate legal and financial complexity for cross-functional stakeholders
  • Strong experience with CLM systems (e.g., Ironclad), eBilling tools, and advanced Excel/Google Sheets modeling skills
  • Deep understanding of SaaS contracting, revenue recognition standards, and vendor management
Responsibilities
  • Act as a "translator" between the legal team and Sales/Finance, accelerating contract review times and minimizing revenue roadblocks
  • Deal Structuring & Advisory: Act as a primary sounding board for sales and leadership on deal structures, ensuring they balance economic objectives with legal risk
  • Deal Structuring Support: Collaborate with Sales/Finance to structure commercial deals, ensuring legal terms align with financial objectives, revenue recognition rules, and risk tolerance
  • Financial Modeling & Forecasting: Develop predictive modeling and scenario planning to support strategic decision-making for complex multi-year deals or departmental growth
  • Business Planning: Support the development of operating forecasts and long-term business plans by partnering cross-functionally to model performance, identify key drivers, and inform strategic decision-making
  • Contract Negotiation: Facilitate negotiations on commercial agreements (sales and vendor) and manage contracting standards and approval matrices
  • Contract Lifecycle Management (CLM): Own and optimize the CLM system to ensure scalable, efficient documentation and clear visibility into deal statuses
  • Playbook Development: Build and maintain negotiation playbooks and template repositories to ensure consistency across all commercial transactions
  • Cross-Functional Liaison: Act as the central point of contact between Legal, Finance, Sales, and IT to align legal workflows with broader company goals
  • Data-Driven Insights: Develop dashboards to track KPIs such as contract turnaround times, spend by matter type, and law firm performance
  • Workflow Efficiency: Design and implement scalable, automated contracting processes (NDAs, MSAs, SaaS agreements) to enable self-service for Sales/Finance teams
  • Knowledge Management: Maintain a centralized repository of contract templates, playbooks, and standardized legal language to ensure consistency
  • Outside Counsel Management: Oversee law firm relationships, billing compliance, and fee structures to control external costs
  • Performance Metrics: Design dashboards to track KPIs such as contract turnaround times, legal spend by matter type, and deal velocity
  • Risk Reporting: Provide CFO with actionable insights on contractual bottlenecks, legal spend risks, and operational inefficiencies

Lirio uses behavioral science and AI to improve patient engagement and health outcomes. Its Precision Nudging personalisation engine analyzes individual behaviors, communication patterns, and social/clinical context to deliver hyper-personalized messages and interventions that encourage adherence and screenings. By moving beyond demographics, it enables real-time, one-to-one outreach to sustain engagement across care journeys, partnering with health systems, payers, and provider organizations. The goal is to reduce gaps in care and lower total cost of care by guiding patients through their evolving healthcare journey.

Company Size

51-200

Company Stage

N/A

Total Funding

$33.1M

Headquarters

Knoxville, Tennessee

Founded

2017

Get referred to Lirio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • October 2025 Precision Nudging for Life Sciences opened a larger pharma market.
  • Cone Health plans five Lirio interventions, showing repeatable enterprise adoption.
  • 2024 Nashville expansion and leadership hires signaled operational scaling beyond Knoxville.

What critics are saying

  • Lirio still lacks visible scaled revenue, despite 2026 seed filings and product launches.
  • Life-sciences messaging faces crowded competition from Salesforce, Veeva, and patient-support vendors.
  • If pharma pilots stall, Lirio's niche platform becomes a services-heavy science project.

What makes Lirio unique

  • Precision Nudging pairs behavioral science with agentic AI and omnichannel activation.
  • Lirio expanded from health systems into life sciences in October 2025.
  • Bon Secours Mercy Health remains a strategic anchor and board-level investor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

10 paid holidays + holiday week company closure

Unlimited Paid Time Off

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Business Wire
Feb 5th, 2026
Life sciences firms struggle with patient engagement as 70% cite adherence challenges costing $100B annually

Lirio, a behavioural science and AI platform, has released research revealing that traditional personalisation approaches in life sciences fail to improve patient engagement. The survey of over 75 life sciences executives, conducted by Sage Growth Partners, found that more than 70% identified clinical trial engagement and medication adherence as persistent challenges. The report highlights that nearly 50% of patients don't take medications as prescribed, contributing to $100 billion in annual preventable healthcare costs and 125,000 avoidable deaths. Despite growing direct-to-consumer strategies, only half of organisations use digital health technologies for patient engagement, and fewer than 3% partner with specialised vendors. The findings come as new regulations reshape pharmaceutical advertising, prompting life sciences companies to rethink patient engagement strategies beyond traditional mass messaging approaches.

Teknovation.biz
May 5th, 2025
Lirio Releases Report Titled (Re)Defining Personalization

Lirio, the Knoxville-based pioneer in the union of behavioral science and artificial intelligence to deliver better health outcomes, has released new industry findings on the significant impact that advanced health... The post Lirio releases report titled (Re)defining Personalization appeared first on Teknovation.biz.

U.S. Securities and Exchange Commission
May 2nd, 2025
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

U.S. Securities and Exchange Commission
May 2nd, 2025
SEC FORM D/A

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Silverwood Partners
Feb 8th, 2024
Healthcare Private Placement and M&A Transactions Review Week Ending Feb 4, 2024 | Silverwood Partners

Strategy | Financing Transactions Private Placement / Financing Transactions Cellanome: The company raised $150 million of Series B venture funding from Premji Invest (US) and undisclosed investors on January 29, 2024, putting the company’s pre-money valuation at $375 million. The company is a developer of a unique multi-omics platform designed to measure biology at an unprecedented […]